• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A vi

tetano

Editor, Senior Moderator
Antiviral Res. 2015 Aug 4. pii: S0166-3542(15)00174-6. doi: 10.1016/j.antiviral.2015.08.001. [Epub ahead of print]
[h=1]Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.[/h] Lee YN[SUP]1[/SUP], Kim MC[SUP]2[/SUP], Lee YT[SUP]1[/SUP], Kim YJ[SUP]1[/SUP], Lee J[SUP]3[/SUP], Kim C[SUP]3[/SUP], Ha SH[SUP]4[/SUP], Kang SM[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Current influenza vaccines are less efficacious against antigenically different influenza A viruses. This study presents an approach to overcome strain-specific protection, using a strategy of co-immunization with seasonal H3N2 split vaccine and yeast-expressed soluble proteins of a tandem repeat containing heterologous influenza M2 ectodomains (M2e5x). Co-immunization with both vaccines in mice was superior to either vaccine alone in inducing cross protection against heterologous H3N2 virus by raising M2e-specific humoral and cellular immune responses toward a T-helper type 1 profile inducing IgG2a isotype antibodies as well as interferon-γ-producing cells in systemic and mucosal sites. In addition, co-immunization sera were found to confer cross-protection against different subtypes of H1N1 and H5N1 influenza A viruses in na?ve mice. A mechanistic study provides evidence that activation of dendritic cells by co-stimulation with M2e5x and split vaccine was associated with the proliferation of CD4[SUP]+[/SUP] T cells. Our results suggest that a strategy of co-immunization with seasonal split and M2e5x protein vaccines could be a promising approach for overcoming the limitation of strain-specific protection by current influenza vaccination.
Copyright ? 2015. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] AS04; Influenza virus; M2e5x; Protein; Split vaccine

PMID: 26248203 [PubMed - as supplied by publisher]
 
Back
Top Bottom